10x Genomics reports FY 2021 revenue $490.5M (+64% YoY); guides FY 2022 revenue $600-630M

10x Genomics, Inc.

2021-FY EPS reported -$0.53 revenue$490,490,000

Revenue $490.5M FY 2021, up 64% from $298.8M in FY 2020; Q4 revenue $143.5M, up 28% from $112.2M.
Gross margin 85% FY 2021 vs 80% in 2020, due to lower royalties and manufacturing efficiencies.
Operating loss $52.3M FY 2021 vs $534.1M in 2020, which included $447.5M acquisition-related R&D charges.
Net loss $58.2M FY 2021 vs $542.7M in 2020; cash and equivalents $587.4M as of Dec 31, 2021.
FY 2022 revenue guidance $600-630M, representing 22-28% growth over FY 2021.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.